Everett Harris & Co. CA boosted its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 9.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 9,328 shares of the biopharmaceutical company’s stock after buying an additional 800 shares during the period. Everett Harris & Co. CA’s holdings in Bristol-Myers Squibb Company were worth $507,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in BMY. Investment Counsel Inc. boosted its position in Bristol-Myers Squibb Company by 17.0% in the first quarter. Investment Counsel Inc. now owns 28,882 shares of the biopharmaceutical company’s stock worth $1,571,000 after buying an additional 4,190 shares during the last quarter. Kanawha Capital Management LLC boosted its position in Bristol-Myers Squibb Company by 3.6% in the first quarter. Kanawha Capital Management LLC now owns 70,078 shares of the biopharmaceutical company’s stock worth $3,811,000 after buying an additional 2,403 shares during the last quarter. Physicians Financial Services Inc. boosted its position in Bristol-Myers Squibb Company by 0.4% in the first quarter. Physicians Financial Services Inc. now owns 9,929 shares of the biopharmaceutical company’s stock worth $540,000 after buying an additional 39 shares during the last quarter. 1ST Source Bank boosted its position in Bristol-Myers Squibb Company by 11.7% in the first quarter. 1ST Source Bank now owns 73,882 shares of the biopharmaceutical company’s stock worth $4,017,000 after buying an additional 7,728 shares during the last quarter. Finally, Polaris Greystone Financial Group LLC purchased a new position in Bristol-Myers Squibb Company during the first quarter worth about $15,109,000. Hedge funds and other institutional investors own 69.77% of the company’s stock.

Institutional Ownership by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)

Shares of Bristol-Myers Squibb Company (BMY) opened at 54.46 on Friday. The company has a market cap of $89.72 billion, a price-to-earnings ratio of 18.92 and a beta of 1.19. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $77.12. The company’s 50-day moving average is $54.40 and its 200 day moving average is $55.01.

Bristol-Myers Squibb Company (NYSE:BMY) last posted its earnings results on Thursday, April 27th. The biopharmaceutical company reported $0.84 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.12. The business had revenue of $4.93 billion for the quarter, compared to the consensus estimate of $4.75 billion. Bristol-Myers Squibb Company had a net margin of 24.22% and a return on equity of 31.86%. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.74 EPS. Equities analysts anticipate that Bristol-Myers Squibb Company will post $2.95 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 2.86%. The ex-dividend date is Wednesday, July 5th. Bristol-Myers Squibb Company’s dividend payout ratio (DPR) is 54.17%.

WARNING: “Bristol-Myers Squibb Company (BMY) Shares Bought by Everett Harris & Co. CA” was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/bristol-myers-squibb-company-bmy-shares-bought-by-everett-harris-co-ca-2/1371886.html.

A number of equities analysts have issued reports on the stock. BidaskClub upgraded shares of Bristol-Myers Squibb Company from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. Vetr upgraded shares of Bristol-Myers Squibb Company from a “buy” rating to a “strong-buy” rating and set a $58.88 price objective on the stock in a research report on Monday, June 5th. Jefferies Group LLC restated a “buy” rating and issued a $64.00 price objective on shares of Bristol-Myers Squibb Company in a research report on Monday, June 5th. BMO Capital Markets cut shares of Bristol-Myers Squibb Company from a “market perform” rating to an “underperform” rating and set a $47.00 price objective on the stock. in a research report on Wednesday, May 3rd. Finally, Robert W. Baird assumed coverage on shares of Bristol-Myers Squibb Company in a research report on Tuesday, April 25th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Bristol-Myers Squibb Company has a consensus rating of “Hold” and a consensus price target of $62.41.

In other Bristol-Myers Squibb Company news, Director Lamberto Andreotti sold 34,000 shares of the firm’s stock in a transaction dated Tuesday, March 28th. The shares were sold at an average price of $56.17, for a total transaction of $1,909,780.00. Following the transaction, the director now owns 986,112 shares of the company’s stock, valued at approximately $55,389,911.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 85,000 shares of company stock worth $4,675,000 in the last three months. Insiders own 0.23% of the company’s stock.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.